Recent Publications

For full list of publications see ORCID profile or PubMed

  1. Grünvogel O, Colasanti O, Lee JY, Klöss V, Belouzard S, Reustle A, Esser-Nobis K, Hesebeck-Brinckmann J, Mutz P, Hoffmann K, Mehrabi A, Koschny R, Vondran FWR, Gotthardt D, Schnitzler P, Neumann-Haefelin C, Thimme R, Binder M, Bartenschlager R, Dubuisson J, Dalpke AH, Lohmann V. (2018) Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes. Gastroenterology doi:10.1053/j.gastro.2018.03.020
  2. Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R. (2018) HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology doi: 10.1053/j.gastro.2018.01.044
  3. Willemsen, J., Wicht, O., Wolanski, J.C., Baur, N., Bastian, S., Haas, D.A., Matula, P., Knapp, B., Meyniel-Schicklin, L., Wang, C., Bartenschlager, R., Lohmann, V., Rohr, K., Erfle, H., Kaderali, L., Marcotrigiano, J., Pichlmair, A. and Binder, M. (2017) Phosphorylation-Dependent Feedback Inhibition of RIG-I by DAPK1 Identified by Kinome-wide siRNA Screening. Molecular Cell 65 (3):403–415
  4. Stanifer ML, Rippert A, Kazakov A, Willemsen J, Bucher D, Bender S, Bartenschlager R, Binder M, Boulant S. (2016) Reovirus intermediate subviral particles constitute a strategy to infect intestinal epithelial cells by exploiting TGF-β dependent pro-survival signaling. Cellular Microbiology doi: 10.1111/cmi.12626 
  5. Grünvogel O, Esser-Nobis K, Windisch MP, Frese M, Trippler M, Bartenschlager R, Lohmann V, Binder M. (2015) Type I and type II interferon responses in two human liver cell lines (Huh-7 and HuH6). Genomics Data 7: 166–170
  6. Trotard M, Tsopoulidis N, Tibroni N, Willemsen J, Binder M, Ruggieri A, et al. Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING. J Virol. doi:10.1128/JVI.02966-15
  7. Bender S, Reuter A, Eberle F, Einhorn E, Binder M, Bartenschlager R. Activation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus. PLoS Pathog. 11: e1005264.
  8. Grünvogel O, Esser-Nobis K, Reustle A, Schult P, Müller B, Metz P, et al. (2015) DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture. J Virol. 89: 10548–10568
  9. Hiet MS, Bauhofer O, Zayas M, Roth H, Tanaka Y, Schirmacher P, Willemsen J, Grünvogel O, Bender S, Binder M, Lohmann V, Lotteau V, Ruggieri A, Bartenschlager R. (2015) Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00298-6.
  10. Wang H, Flannery SM, Dickhöfer S, Huhn S, George J, et al. (2014) A coding IRAK2 variant compromises TLR signaling and is associated with colorectal cancer survival. J Biol Chem 289: 23123-23131
  11. Binder M, Bartenschlager R (2013) Hepatitis C: a mouse at the end of the tunnel. Cell Research 23: 1343–1344.
  12. Börner K, Niopek D, Cotugno G, Kaldenbach M, Pankert T, et al. (2013) Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res 41: e199–e199.
  13. Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, et al. (2013) Hepatitis C virus targets the interferon-α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett 587: 1571–1578.
  14. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, et al. (2013) Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57: 953–963.
  15. Binder M, Sulaimanov N, Clausznitzer D, Schulze M, Hüber CM, et al. (2013) Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog 9: e1003561.
  16. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, et al. (2012) Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56: 2082–2093.
  17. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, et al. (2012) Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 487: 486–490.
  18. Thimme R, Binder M, Bartenschlager R (2012) Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 36: 663–683.
  19. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, Schmidt J, Nitschke K, et al. (2011) Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54: 1157–1166.
  20. Lee M-H, Lalwani P, Raftery MJ, Matthaei M, Lutteke N, et al. (2011) RNA helicase retinoic acid-inducible gene I as a sensor of Hantaan virus replication. J Gen Virol 92: 2191–2200.
  21. Binder M, Eberle F, Seitz S, Mücke N, Hüber CM, et al. (2011) Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem 286: 27278–27287.
  22. Knapp B, Rebhan I, Kumar A, Matula P, Kiani NA, et al. (2011) Normalizing for individual cell population context in the analysis of high-content cellular screens. BMC Bioinformatics 12: 485.
  23. Backes P, Quinkert D, Reiss S, Binder M, Zayas M, et al. (2010) Role of annexin A2 in the production of infectious hepatitis C virus particles. J Virol 84: 5775–5789.
  24. Eberle F, Sirin M, Binder M, Dalpke AH (2009) Bacterial RNA is recognized by different sets of immunoreceptors. Eur J Immunol 39: 2537–2547.
  25. Binder M, Kochs G, Bartenschlager R, Lohmann V (2007) Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46: 1365–1374.
  26. Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, et al. (2007)Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. The Journal of Virology 81: 5270–5283.
  27. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167–1172.

to top